Cue Biopharma ( NASDAQ:CUE – Get Free Report ) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Cue Biopharma to related businesses based on the strength of its institutional ownership, risk, earnings, analyst recommendations, valuation, profitability and dividends.
Volatility and Risk
Cue Biopharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, Cue Biopharma’s rivals have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.
Get Cue Biopharma alerts:
Earnings & Valuation
This table compares Cue Biopharma and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio
Cue Biopharma $27.47 million -$26.60 million -0.69
Cue Biopharma Competitors $705.29 million $10.71 million -15.00
Cue Biopharma’s rivals have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of current ra...